Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus: Effects on Lipids, Mental State and Fibrinolysis

Visseren, F.L.J.; Bouter, P.K.; van Loon, B.J.P.; Erkelens, W.D.
October 2001
Clinical Drug Investigation;2001, Vol. 21 Issue 10, p671
Academic Journal
Objective: To determine the effects of fluvastatin on lipids, mood and fibrinolysis in dyslipidaemic patients with type 2 diabetes mellitus. Design and Setting: Randomised, double-blind, placebo-controlled study in 12 outpatient clinics of general hospitals in The Netherlands evaluating the use of the HMG-CoA reductase inhibitor fluvastatin for dyslipidaemia [low-density lipoprotein (LDL)-cholesterol >4.1 mmol/L] in patients with type 2 diabetes mellitus receiving insulin therapy. Effects on lipids, lipoproteins, fibrinolysis and mood were evaluated. Patients: 42 patients with type 2 diabetes mellitus and dyslipidaemia (LDL-cholesterol >4.1 mmol/L) were treated with fluvastatin 40mg once daily and 45 patients received placebo for 12 weeks followed by open-label treatment with fluvastatin for 12 weeks. Results: Fluvastatin reduced serum levels of LDL-cholesterol by 25.5% (p < 0.05) compared with placebo after 12 weeks of treatment, but did not affect the levels of the fibrinolytic parameters plasminogen activator inhibitor-1 (PAI-1) and tissue-plasminogen activator (t-PA) or the levels of lipoproteins Lp(a) and apolipoprotein (Apo) A1. Fluvastatin also did not change the mental status of patients with type 2 diabetes mellitus as assessed with the Zung questionnaire. Adverse reactions were equally distributed between the fluvastatin and placebo groups. Conclusions: In conclusion, fluvastatin treatment for dyslipidaemia in patients with type 2 diabetes mellitus on insulin therapy is effective and well tolerated. Fibrinolysis and mood were not affected by this treatment.


Related Articles

  • Nature Medicine: Scientists uncover potential treatment for painful side effect of diabetes.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article informs that a potential treatment for the side effects of diabetes has been discovered by the scientists.

  • Gene Regulation of Aldose-, Aldehyde- and a Renal Specific Oxido Reductase (RSOR) in the Pathobiology of Diabetes Mellitus. Farhad R. Danesh; Jun Wada; Elisabeth I. Wallner; Atul Sahai; Satish K. Srivastava; Yashpal S. Kanwar // Current Medicinal Chemistry;Aug2003, Vol. 10 Issue 15, p1399 

    Aldose-, aldehyde and renal specific oxido reductase (RSOR) belong to the family of aldo-keto reductases (AKRs). They are monomeric (a / �)8-barrel proteins with a molecular weight ranging from 30 to 40 kDa, and at present include more than 60 members. Except for RSOR, they are expressed in...

  • NOX enzymes and diabetic complications. Kakehi, Tomoko; Yabe-Nishimura, Chihiro // Seminars in Immunopathology;2008, Vol. 30 Issue 3, p301 

    Several molecular mechanisms have been identified that mediate the tissue-damaging effects of hyperglycemia. These are increased flux through the polyol and hexosamine pathways, increased formation of advanced glycation end products, activation of protein kinase C, and augmented generation of...

  • Authors Reply. Subramanian, Usha // JGIM: Journal of General Internal Medicine;Feb2010, Vol. 25 Issue 2, p172 

    A response by Usha Subramanian to a letter to the editor about her article "Open Access Implementation and Diabetes Outcomes" in the 2009 issue of the journal is presented.

  • Diabetic Nephropathy.  // Diabetes Care;Jan2000 Supplement 1, Vol. 23, pS69 

    Provides recommendations regarding the detection and treatment of diabetic nephropathy. History of diabetic nephropathy; How to screen for albuminuria; Information on the use of antihypertensive agents.

  • Pyridoxal phosphate prevents progression of diabetic nephropathy. Sakurako Nakamura; Hongyan Li; Ayinuer Adijiang; Monika Pischetsrieder; Toshimitsu Niwa // Nephrology Dialysis Transplantation;Aug2007, Vol. 22 Issue 8, p2165 

    Background. We have demonstrated that pyridoxal 5′-phosphate (PLP), an active form of vitamin B6, inhibits formation of advanced glycation end-products (AGEs) by trapping 3-deoxyglucosone. The present study aimed to clarify if PLP could exert beneficial effects on nephropathy in...

  • B6 Vitamers: Natural Protection Against the Complications of Diabetes and Accelerated Aging. Goepp, Julius // Life Extension;Jul2009, Vol. 15 Issue 7, p50 

    The article discusses a study on the benefits of B6 vitamers as natural protection against diabetes complications and aging. It mentions the biochemical process known as glycation, wherein sugars react with proteins to generate cross-links or advanced glycation end products. Glycation causes...

  • Aspirin therapy in diabetes.  // Clinical Diabetes;1998, Vol. 16 Issue 2, p75 

    Focuses on the findings of investigators on the use of aspirin therapy in patients diagnosed with diabetes for treatment of cardiovascular complications. Indepth look at the evidence they found; How aspirin works when used for treatment of the complications; Detailed information on secondary...

  • Osteoporosis: An Under-appreciated Complication of Diebetes. Brown, Sue A.; Sharpless, Julie L. // Clinical Diabetes;Winter2004, Vol. 22 Issue 1, p10 

    Presents information on diabetes-related osteoporosis. Definition of osteoporosis; Annual average number of bone fractures in the U.S.; Risk factors for osteoporotic fractures in diabetes; Measures to prevent osteoporosis; Clinical considerations for therapeutic interventions; Treatment options...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics